Nystatin: Difference between revisions
ClaireLewis (talk | contribs) |
(Add AntibioticDose SMW query table for dynamic indications by disease) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 14: | Line 14: | ||
*Intestinal candidiasis | *Intestinal candidiasis | ||
**1-2 tabs (500,000 U) PO TID until 48 hrs after symptoms resolve | **1-2 tabs (500,000 U) PO TID until 48 hrs after symptoms resolve | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Nystatin]] [[Has Population::Adult]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Nystatin]] [[Has Population::Pediatric]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
===Oral [[candidiasis]]=== | ===Oral [[candidiasis]]=== | ||
*Premature neonates: | *Premature neonates: | ||
| Line 59: | Line 83: | ||
==See Also== | ==See Also== | ||
*[[Antifungals]] | |||
*[[Fungal infections]] | |||
==References== | ==References== | ||
Latest revision as of 20:38, 20 March 2026
Administration
- Type: Antifungal
- Dosage Forms:
- Routes of Administration:
- PO
- Topical
- Vaginal
- Common Trade Names: Nystop, Nyamyc
Adult Dosing
Candidiasis
- Oral candidiasis
- 4-6 mL PO QID of 100,000U/mL until 48 hrs after symptoms resolve
- Intestinal candidiasis
- 1-2 tabs (500,000 U) PO TID until 48 hrs after symptoms resolve
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Balanoposthitis | cream 100,000 units/gm if infection is recurrent after clotrimazole therapy | Antifungal, Recurrent |
| Oropharyngeal candidiasis | oral suspension 400,000-600,000 units (swish and swallow) Q6H until 48 hours after symptoms disappear | Adult |
Pediatric Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Oropharyngeal candidiasis | Oral Suspension 100,000 units/ml for 14 days for all ages | Pediatric |
Oral candidiasis
- Premature neonates:
- 1 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
- Infants:
- 2 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
- Children:
- 4-6 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
Special Populations
- Pregnancy Rating: C
- Lactation risk: Safe
Renal Dosing
- Adult: not defined
- Pediatric: not defined
Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hypersensitivity reaction
Common
Pharmacology
- Half-life: unknown
- Metabolism: CYP450
- Excretion: Feces
Mechanism of Action
- Increases cell membrane permeability by binding to sterols